Kronos Bio to Present Data at ACR Convergence 2024 to Support p300 KAT Inhibition as an Approach to Anti-Inflammatory Therapy

Core Insights - Kronos Bio, Inc. is developing a p300 KAT inhibitor aimed at treating autoimmune diseases, with preclinical data to be presented at the ACR Convergence 2024 meeting [1][2][3] - The company is on track to announce a development candidate for autoimmune diseases by the end of 2024 [2][3] Company Overview - Kronos Bio is a clinical-stage company focused on small molecule therapeutics that target deregulated transcription, which is associated with cancer and other diseases [4] - The company utilizes a proprietary discovery engine to decode transcription factor regulatory networks, identifying druggable cofactors for therapeutic development [4] - Kronos Bio has a preclinical pipeline that includes two drug candidates: KB-0742 targeting CDK9 for MYC deregulation in solid tumors and KB-9558 targeting p300 for IRF4 dependence in multiple myeloma [4]